image
Healthcare - Biotechnology - NASDAQ - US
$ 12.63
1.94 %
$ 1.31 B
Market Cap
-2.31
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one NTLA stock under the worst case scenario is HIDDEN Compared to the current market price of 12.6 USD, Intellia Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one NTLA stock under the base case scenario is HIDDEN Compared to the current market price of 12.6 USD, Intellia Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one NTLA stock under the best case scenario is HIDDEN Compared to the current market price of 12.6 USD, Intellia Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NTLA

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
57.9 M REVENUE
59.55%
-534 M OPERATING INCOME
-3.68%
-519 M NET INCOME
-7.86%
-349 M OPERATING CASH FLOW
11.47%
126 M INVESTING CASH FLOW
500.57%
186 M FINANCING CASH FLOW
42.53%
16.6 M REVENUE
29.15%
-121 M OPERATING INCOME
11.46%
-114 M NET INCOME
11.30%
-149 M OPERATING CASH FLOW
-74.81%
94.3 M INVESTING CASH FLOW
-37.76%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Intellia Therapeutics, Inc.
image
Current Assets 640 M
Cash & Short-Term Investments 602 M
Receivables 8.52 M
Other Current Assets 29.8 M
Non-Current Assets 551 M
Long-Term Investments 44.3 M
PP&E 247 M
Other Non-Current Assets 260 M
50.50 %3.72 %20.71 %21.85 %Total Assets$1.2b
Current Liabilities 111 M
Accounts Payable 14.6 M
Short-Term Debt 20.2 M
Other Current Liabilities 76 M
Non-Current Liabilities 208 M
Long-Term Debt 380 M
Other Non-Current Liabilities -172 M
4.57 %6.35 %23.83 %119.07 %Total Liabilities$319.1m
EFFICIENCY
Earnings Waterfall Intellia Therapeutics, Inc.
image
Revenue 57.9 M
Cost Of Revenue 0
Gross Profit 47.6 M
Operating Expenses 592 M
Operating Income -534 M
Other Expenses -15.2 M
Net Income -519 M
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)58m048m(592m)(534m)15m(519m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
82.23% GROSS MARGIN
82.23%
-923.10% OPERATING MARGIN
-923.10%
-896.77% NET MARGIN
-896.77%
-59.52% ROE
-59.52%
-43.58% ROA
-43.58%
-48.55% ROIC
-48.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Intellia Therapeutics, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)(450m)(450m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -519 M
Depreciation & Amortization 10.3 M
Capital Expenditures -5.78 M
Stock-Based Compensation 154 M
Change in Working Capital 0
Others -29.2 M
Free Cash Flow -355 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Intellia Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for NTLA of $33.4 , with forecasts ranging from a low of $9 to a high of $60 .
NTLA Lowest Price Target Wall Street Target
9 USD -28.74%
NTLA Average Price Target Wall Street Target
33.4 USD 164.45%
NTLA Highest Price Target Wall Street Target
60 USD 375.06%
Price
Max Price Target
Min Price Target
Average Price Target
60605050404030302020101000Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Intellia Therapeutics, Inc.
image
Sold
0-3 MONTHS
66.3 K USD 4
3-6 MONTHS
31.9 K USD 3
6-9 MONTHS
831 K USD 7
9-12 MONTHS
38.2 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy' Investors often react fast to news. We see it with earnings announcements. And in biotech/pharma, we see it in response to news about drug trials. We saw that in spades on 5/29/25 for gene editor Intellia Therapeutics. The stock lost 29% after news of a “safety concern” surfaced during a Phase III drug trial. The news looked terrible. A lab test showed indications that a patient was experiencing an emergency liver problem. But the asymptomatic condition quickly corrected on its own. seekingalpha.com - 4 days ago
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a previous ceiling of 6,500, and flagged three stocks investors should have on their radar, including two index stalwarts and one off-the-beaten-path growth opportunity. marketbeat.com - 1 week ago
Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth. 247wallst.com - 1 week ago
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. globenewswire.com - 2 weeks ago
Intellia Gains 29.8% in a Month: How Should You Play the Stock? NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention. zacks.com - 2 weeks ago
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains. zacks.com - 3 weeks ago
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. globenewswire.com - 1 month ago
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. globenewswire.com - 1 month ago
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation. zacks.com - 1 month ago
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course Intellia Therapeutics Inc NTLA said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Phase 3 MAGNITUDE study. benzinga.com - 1 month ago
Analysts Think These Stocks Could More Than Double in Value Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk. marketbeat.com - 1 month ago
8. Profile Summary

Intellia Therapeutics, Inc. NTLA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.31 B
Dividend Yield 0.00%
Description Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Contact 40 Erie Street, Cambridge, MA, 02139 https://www.intelliatx.com
IPO Date May 6, 2016
Employees 403
Officers Mr. James E. Basta Esq., J.D. Executive Vice President, General Counsel & Corporate Secretary Mr. Edward J. Dulac III Executive Vice President, Chief Financial Officer and Treasurer Mr. Michael P. Dube Vice President, CAO & Principal Accounting Officer Dr. Laura Sepp-Lorenzino Ph.D. Special Advisor to the Chief Executive Officer Dr. Rachel E. Haurwitz Ph.D. Co-Founder Dr. Andrew May Ph.D. Founder and Member of Scientific Advisor Board Dr. Derrick J. Rossi Ph.D. Founder & Member of Scientific Advisor Board Dr. John M. Leonard M.D. President, Chief Executive Officer & Director Dr. David Lebwohl M.D. Executive Vice President & Chief Medical Officer Dr. Jennifer A. Doudna Ph.D. Founder & Member of Scientific Advisor Board